Literature DB >> 24096788

Should we listen and talk more to our patients?

Dieter Naber1, Martin Lambert.   

Abstract

Entities:  

Year:  2013        PMID： 24096788      PMCID： PMC3799253          DOI： 10.1002/wps.20066

Source DB:  PubMed          Journal:  World Psychiatry        ISSN： 1723-8617            Impact factor:   49.548


× No keyword cloud information.
  10 in total

1.  Assertive community treatment as part of integrated care versus standard care: a 12-month trial in patients with first- and multiple-episode schizophrenia spectrum disorders treated with quetiapine immediate release (ACCESS trial).

Authors:  Martin Lambert; Thomas Bock; Daniel Schöttle; Dietmar Golks; Klara Meister; Liz Rietschel; Alexandra Bussopulos; Marietta Frieling; Michael Schödlbauer; Marc Burlon; Christian G Huber; Gunda Ohm; Manoshi Pakrasi; Michael Sadre Chirazi-Stark; Dieter Naber; Benno G Schimmelmann
Journal:  J Clin Psychiatry       Date:  2010-03-23       Impact factor: 4.384

2.  Clozapine for treatment-resistant schizophrenia: National Institute of Clinical Excellence (NICE) guidance in the real world.

Authors:  Ann M Mortimer; Praveen Singh; Charles J Shepherd; Junais Puthiryackal
Journal:  Clin Schizophr Relat Psychoses       Date:  2010-04

3.  Attitudes toward antipsychotic medication: the impact of clinical variables and relationships with health professionals.

Authors:  Jennifer C Day; Richard P Bentall; Chris Roberts; Fiona Randall; Anne Rogers; Dinah Cattell; David Healy; Pam Rae; Cheryl Power
Journal:  Arch Gen Psychiatry       Date:  2005-07

4.  Time to discontinuation of first- and second-generation antipsychotic medications in the treatment of schizophrenia.

Authors:  Julie Kreyenbuhl; Eric P Slade; Deborah R Medoff; Clayton H Brown; Benjamin Ehrenreich; Joseph Afful; Lisa B Dixon
Journal:  Schizophr Res       Date:  2011-05-14       Impact factor: 4.939

5.  Psychiatrists' attitude to antipsychotic depot treatment in patients with first-episode schizophrenia.

Authors:  S Heres; T Reichhart; J Hamann; R Mendel; S Leucht; W Kissling
Journal:  Eur Psychiatry       Date:  2010-06-08       Impact factor: 5.361

6.  Does long-acting injectable risperidone make a difference to the real-life treatment of schizophrenia? Results of the Cohort for the General study of Schizophrenia (CGS).

Authors:  Lamiae Grimaldi-Bensouda; Frederic Rouillon; Bernard Astruc; Michel Rossignol; Jacques Benichou; Bruno Falissard; Frederic Limosin; Beatrice Beaufils; Guillaume Vaiva; Helene Verdoux; Yola Moride; Alban Fabre; Florence Thibaut; Lucien Abenhaim
Journal:  Schizophr Res       Date:  2011-11-30       Impact factor: 4.939

7.  A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia.

Authors:  Jari Tiihonen; Jari Haukka; Mark Taylor; Peter M Haddad; Maxine X Patel; Pasi Korhonen
Journal:  Am J Psychiatry       Date:  2011-03-01       Impact factor: 18.112

8.  Association of subjective well-being, symptoms, and side effects with compliance after 12 months of treatment in schizophrenia.

Authors:  Anne Karow; Joerg Czekalla; Ralf W Dittmann; Alexander Schacht; Thomas Wagner; Martin Lambert; Benno G Schimmelmann; Dieter Naber
Journal:  J Clin Psychiatry       Date:  2007-01       Impact factor: 4.384

Review 9.  Integrated care in patients with schizophrenia: results of trials published between 2011 and 2013 focusing on effectiveness and efficiency.

Authors:  Daniel Schöttle; Anne Karow; Benno G Schimmelmann; Martin Lambert
Journal:  Curr Opin Psychiatry       Date:  2013-07       Impact factor: 4.741

10.  Resource Group Assertive Community Treatment (RACT) as a Tool of Empowerment for Clients with Severe Mental Illness: A Meta-Analysis.

Authors:  Tommy Nordén; Ulf Malm; Torsten Norlander
Journal:  Clin Pract Epidemiol Ment Health       Date:  2012-11-16
  10 in total
  1 in total

1.  The customer is always right? Subjective target symptoms and treatment preferences in patients with psychosis.

Authors:  Steffen Moritz; Fabrice Berna; Susanne Jaeger; Stefan Westermann; Matthias Nagel
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2016-05-18       Impact factor: 5.270
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.